CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Revlimid (CC-5013)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00396045
NCT00396045Phase 2Completed
CompareCT.gov

A Multicenter, Open Label Study of Oral Melphalan, Prednisone, and CC-5013 (Revlimid) (MPR) as Induction Therapy in Elderly Newly Diagnosed Multiple Myeloma Patients

University of Turin, Italy·interventional·Posted Nov 6, 2006·Updated Nov 30, 2006

In Brief

A Phase 2 clinical trial evaluating Revlimid (CC-5013) for Multiple Myeloma. Completed, across 9 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of the association of Melphalan/Prednisone/Revlimid (MPR) as induction treatment for newly diagnosed myeloma patients over age 65 or those under 65 years who refuse or are not eligible for high dose therapy. This association might further increase the response rate achieved by the standard oral MP regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesItaly
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 6, 2006
Enrollment StartJan 1, 2005
Study CompletionJan 1, 2008
TodayJul 2, 2026
Posted 19.7 years ago

Interventions

Revlimid (CC-5013)drug